Last $1.02 USD
Change Today +0.045 / 4.62%
Volume 329.2K
ENZN On Other Exchanges
Symbol
Exchange
NASDAQ CM
Frankfurt
As of 8:10 PM 10/23/14 All times are local (Market data is delayed by at least 15 minutes).

enzon pharmaceuticals inc (ENZN) Snapshot

Open
$0.98
Previous Close
$0.98
Day High
$1.09
Day Low
$0.96
52 Week High
09/2/14 - $1.83
52 Week Low
02/3/14 - $0.78
Market Cap
45.0M
Average Volume 10 Days
235.4K
EPS TTM
$0.63
Shares Outstanding
44.1M
EX-Date
12/24/13
P/E TM
1.6x
Dividend
--
Dividend Yield
44.12%
Current Stock Chart for ENZON PHARMACEUTICALS INC (ENZN)

enzon pharmaceuticals inc (ENZN) Related Businessweek News

No Related Businessweek News Found

enzon pharmaceuticals inc (ENZN) Details

Enzon Pharmaceuticals, Inc. is engaged in licensing drug products. Its marketed drug products include PegIntron for chronic hepatitis C; Sylatron for Melanoma; Macugen for neovascular age-related macular degeneration; CIMZIA for Crohn’s disease; Oncaspar for acute lymphoblastic leukemia; and Adagen for severe combined immunedeficiency. The company was founded in 1981 and is headquartered in Piscataway, New Jersey.

1 Employees
Last Reported Date: 03/14/14
Founded in 1981

enzon pharmaceuticals inc (ENZN) Top Compensated Officers

Interim Principal Executive Officer, Interim ...
Total Annual Compensation: $428.5K
Principal Financial Officer, Principal Accoun...
Total Annual Compensation: --
Consultant
Total Annual Compensation: $158.6K
Compensation as of Fiscal Year 2013.

enzon pharmaceuticals inc (ENZN) Key Developments

Enzon Pharmaceuticals Inc.(NasdaqCM:ENZN) dropped from Russell 2000 Index

Enzon Pharmaceuticals Inc. will be removed from the Russell 2000 Index.

Enzon Pharmaceuticals Inc.(NasdaqCM:ENZN) dropped from Russell 3000 Index

Enzon Pharmaceuticals Inc. will be removed from the Russell 3000 Index.

Enzon Pharmaceuticals Receives Non-Compliance Notice From NASDAQ

On June 10, 2014, Enzon Pharmaceuticals, Inc. received a letter from the Listing Qualifications staff of The NASDAQ Stock Market LLC (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer meets the requirement to maintain a minimum bid price of $1 per share, as set forth in Nasdaq Listing Rule 5550(a)(2). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided a period of 180 calendar days, or until December 8, 2014, in which to regain compliance. In order to regain compliance with the minimum bid price requirement, the closing bid price of the Company’s common stock must be at least $1 per share for a minimum of ten consecutive business days during this 180-day period. In the event that the Company does not regain compliance within this 180-day period, the Company may be eligible to seek an additional compliance period of 180 calendar days if it meets the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, with the exception of the bid price requirement, and provides written notice to Nasdaq of its intent to cure the deficiency during this second compliance period, by effecting a reverse stock split, if necessary. However, if it appears to the Nasdaq Staff that the Company will not be able to cure the deficiency, or if the Company is otherwise not eligible, Nasdaq will provide notice to the Company that its common stock will be subject to delisting. The Notice does not result in the immediate delisting of the Company’s common stock from the Nasdaq Capital Market. The Company intends to monitor the closing bid price of the Company’s common stock and consider its available options in the event that the closing bid price of the Company’s common stock remains below $1 per share. There can be no assurance that the Company will be able to regain compliance with the minimum bid price requirement or maintain compliance with the other listing requirements.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ENZN:US $1.02 USD +0.045

ENZN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Depomed Inc $15.22 USD +0.34
Emergent Biosolutions Inc $21.60 USD +0.29
Onxeo €6.52 EUR -0.30
Regulus Therapeutics Inc $14.54 USD +0.79
Veloxis Pharmaceuticals A/S kr2.06 DKK 0.00
View Industry Companies
 

Industry Analysis

ENZN

Industry Average

Valuation ENZN Industry Range
Price/Earnings 1.6x
Price/Sales 1.3x
Price/Book 2.1x
Price/Cash Flow 1.6x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ENZON PHARMACEUTICALS INC, please visit www.enzon.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.